Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biohaven Ltd. Common Shares (NY:BHVN)

20.25 +1.23 (+6.47%)
Official Closing Price Updated: 4:00 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biohaven Ltd. Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Biohaven Pharmaceutical's Return On Capital Employed Insights
Biohaven Pharmaceutical (NYSE:BHVN) brought in sales totaling $190.01 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 15.81%, resulting... 
Via Benzinga
Biohaven Stock Dives As 'Hand-Wringing' Clouds Two Potentially Promising Deals
Biohaven inked a pair of deals that one analyst find promising for its pipeline. 
Via Investor's Business Daily
Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences Deals
Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) has entered into a global license agreement with Bristol Myers Squibb & Co (NYSE: BMY) to... 
Via Benzinga
The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Lilly's Co-developed Diabetes Drug Jardiance Gets Label Expansion To... 
Via Benzinga
Biohaven Pharma: Q4 Earnings Insights
Biohaven Pharma Hldgs (NYSE:BHVN) reported its Q4 earnings results on Friday, February 25, 2022 at 07:30 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Where Biohaven Pharma Hldgs Stands With Analysts
Analysts have provided the following ratings for Biohaven Pharma Hldgs (NYSE:BHVN... 
Via Benzinga
Analyst Ratings For Biohaven Pharma Hldgs
Within the last quarter, Biohaven Pharma Hldgs (NYSE:BHVN) has observed the f... 
Via Benzinga
Earnings Scheduled For February 25, 2022
Companies Reporting Before The Bell • ACM Research (NASDAQ:ACMR) is estimated to report quarterly earnings at $0.64 per share on revenue of $89.53 million. •... 
Via Benzinga
Biohaven Pharmaceutical's Earnings Outlook
Biohaven Pharmaceutical (NYSE:BHVN) is set to give its latest quarterly earnings report on Friday, 2022-02-25. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Biohaven/Pfizer Partnered Rimegepant Asia-Pacific Migraine Trial Meets Primary Endpoints
Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) and Pfizer Inc (NYSE: PFE) reported topline results from an Asia-Pacific, Phase 3 trial of... 
Via Benzinga
New Psychedelics ETF Launches On NYSE Arca
Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)... 
Via Benzinga
This Tattooed, Cowboy-Boot-Wearing Top CEO Refuses To Go Clean Cut
John Chiminski knows he doesn't fit the traditional image of a corporate bigwig. And the Catalent CEO is not about to change. 
Via Investor's Business Daily
2022 Could be a Banner Year for Biotech Stocks as per top managers (SPRC, HOTH, NLSP, PSTV, IMMX, GNPX, NRBO)
Via AB Newswire
The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug Sales
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Illumina Announces Co-Development Partnership With SomaScan For Accelerating... 
Via Benzinga
Biohaven's Zavegepant Pain Spray Aces Late-Stage Migraine Trial
Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) is eyeing filing for approval in early 2022 for its experimental pain spray after new data showed it hit its... 
Via Benzinga
What 6 Analyst Ratings Have To Say About Biohaven Pharma Hldgs
Within the last quarter, Biohaven Pharma Hldgs (NYSE:BHVN) has observed the ... 
Via Benzinga
75 Biggest Movers From Yesterday
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Check out these big penny stock gainers and losers... 
Via Benzinga
Pfizer Gains Outside US Rights To Biohaven's Migraine Treatment For $500M
Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) and Pfizer Inc (NYSE: PFE) have announced an agreement for rimegepant in markets outside the U.S.... 
Via Benzinga
58 Stocks Moving In Monday's Mid-Day Session
Gainers Dover Motorsports, Inc. (NYSE: DVD) shares climbed 60.3% to $3.59 after Speedway Motorsports announced it will acquire the company for $3.61 per share in cash. TDH... 
Via Benzinga
Why Biohaven Pharmaceuticals Stock Crumbled On This Premium Deal With Pfizer
Biohaven will receive up to $1.24 billion in payments under a deal for Nurtec ODT. 
Via Investor's Business Daily
Jim Cramer: MGM Resorts Has Good Top Management
On CNBC’s "Mad Money Lightning Round," Jim Cramer said MGM Resorts International (NYSE: MGM) has a lot of good top management. With Wynn Resorts, Limited (NASDAQ... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Compass Pathways (NASDAQ:CMPS) shares rose 18.43% to $51.0 during Tuesday's pre-market session. The company's market cap stands at $2.1 billion. As per the... 
Via Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Cramer Likes American Eagle Outfitters And These 2 Pharma Stocks
On CNBC’s “ 
Via Benzinga
Where Biohaven Pharma Hldgs Stands With Analysts
Analysts have provided the following ratings for Biohaven Pharma Hldgs (NYSE:BHV... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Goldman Sachs lowered the price target on Nucor Corporation (NYSE: 
Via Benzinga
What 7 Analyst Ratings Have To Say About Biohaven Pharma Hldgs
Biohaven Pharma Hldgs (NYSE:BHVN) has observed the following analyst ratings... 
Via Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.